In short
Currently, there is 1 ongoing clinical trial focused on treating Pseudomonas infection, specifically investigating the optimal duration of antibiotic therapy for patients with Pseudomonas aeruginosa blood infections. This trial is being conducted in Spain and compares 7-day versus 14-day antibiotic treatment regimens.
Clinical trial locations
Study on the Effectiveness and Safety of 7 vs. 14 Days of Antibiotic Treatment with Meropenem for Patients with Pseudomonas Aeruginosa Blood Infection
This trial is focused on treating blood infections caused by Pseudomonas aeruginosa, a type of bacteria that can be difficult to eliminate and is often resistant to many antibiotics. The infection occurs when this bacterium enters the bloodstream, typically spreading from another part of the body such as the lungs or urinary tract. Symptoms may include fever, chills, and low blood pressure, and without proper treatment, the infection can lead to serious complications.
Main inclusion criteria:
- Adults aged 18 years or older
- Confirmed bacteremia caused by Pseudomonas aeruginosa
- Must have already received 6 days (plus or minus 1 day) of active antibiotic treatment before joining the study
- Must sign an informed consent form agreeing to participate in the trial
Main exclusion criteria:
- Patients with infections caused by bacteria other than Pseudomonas aeruginosa
- Those currently participating in another clinical trial
- Known allergy to the antibiotics being studied
- Pregnant or breastfeeding women
- Patients with severe medical conditions affecting the heart, liver, or kidneys that might interfere with the study
- Individuals with weakened immune systems
- Those unable to follow study procedures or instructions
Trial focus and goal:
The main goal of this study is to determine whether a shorter 7-day course of antibiotic treatment is as effective and safe as the traditional 14-day course. Researchers want to find out if they can reduce the duration of treatment without compromising patient recovery, while also lowering the risk of serious side effects and reducing overall antibiotic exposure. This is particularly important because overuse of antibiotics can contribute to antibiotic resistance.
Participants will be randomly assigned to receive either 7 or 14 days of antibiotic treatment. Their health and recovery will be closely monitored, with researchers checking for any return of the infection, side effects, or other health problems. The effectiveness of the treatment will be assessed using a specialized method that ranks outcomes based on how desirable they are for the patient.
Investigational drugs:
The trial involves a range of antibiotics that can be used to treat this type of infection. The main antibiotic being studied is Meropenem, but other antibiotics may also be used depending on the patient's specific situation. These include Aztreonam, Levofloxacin, Amikacin, Colistimethate Sodium, Ciprofloxacin, Ceftazidime, Tobramycin, Imipenem, Cilastatin, Piperacillin, Tazobactam, Cefiderocol, Avibactam, Vaborbactam, and Delafloxacin.
Some of these medications are given through an IV drip directly into the bloodstream, while others can be taken as tablets by mouth. One notable combination is Piperacillin/Tazobactam, which works by preventing bacteria from building their protective cell walls while also blocking enzymes that bacteria use to resist antibiotics.
The study will track several important outcomes, including survival rates, clinical cure, treatment failure, new infections, serious adverse events, length of hospital stay, and any recurrence of the infection. These outcomes will be assessed at 30 days and 90 days after completing antibiotic treatment.
Summary
Currently, only one clinical trial is actively recruiting patients for Pseudomonas infection, specifically focusing on bloodstream infections caused by Pseudomonas aeruginosa. This trial is being conducted in Spain and represents an important effort to optimize antibiotic treatment duration. The research addresses a critical question in infectious disease management: whether shorter antibiotic courses can be as effective as longer ones while reducing potential side effects and antibiotic exposure.
The trial is notable for its comprehensive approach, testing multiple antibiotic options and using advanced methods to evaluate treatment outcomes. The focus on comparing 7-day versus 14-day treatment regimens could have significant implications for future treatment guidelines if shorter courses prove to be equally effective. This is particularly relevant given the increasing concerns about antibiotic resistance and the need to minimize unnecessary antibiotic use.
Patients interested in participating should note that they must already be receiving treatment for Pseudomonas aeruginosa bacteremia and meet specific eligibility criteria related to their overall health status and ability to comply with study procedures.
